Please join us for this free online scientific webinar on the 9th June 2022 at 13:00 BST, where you will learn how Olink’s unique proteomic technology which is offered at Leeds Immunogenomic Core Facility in the LIGHT Laboratories is empowering scientists to explore the dynamic proteome within precision medicine research. Demonstrating that the Olink protein library covers all major biological pathways which cover numerous research fields across cancer, cardiovascular, neurological, immunological and inflammatory disorders.
Themes to be included will be:
We are greatly honoured to have Dr. James Peters speaking who has worked closely with Leeds Immunogenomic Core Facility to apply the Olink technology within his own research. Dr. Peters will present how his group used a multiomic approach with plasma proteomics, RNA-sequencing and flow cytometry of immune cells, to identify distinct transcriptomic and proteomic molecular temporal profiles of COVID-19 disease severity. The plasma proteome was found to be a superior indicator of clinical severity than the PBMC transcriptome.
Others include Anne-Li Lind, PhD and Neuroscience Specialist from Olink’s Scientific Affairs Team. Anne-Li will present case studies and published findings on longitudinal examination of treatment responses in the context of oncology research. As well as the use of Olink’s Proximity Extension Assay (PEA) Technology in plasma and cerebrospinal fluid for defining protein signatures for disease classification and disease progression in dementia research.
Faculty of Medicine, Department of Immunology and Inflammation
Imperial College London
Scientific Communications Representative
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.